Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 13
2008 24
2009 16
2010 18
2011 15
2012 22
2013 17
2014 11
2015 16
2016 16
2017 16
2018 7
2019 13
2020 24
2021 33
2022 26
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A, Christiaens M, Polterauer S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Lorusso D, et al. Among authors: zagouri f. Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9. Epub 2024 Mar 20. Lancet. 2024. PMID: 38521086 Clinical Trial.
Cardiovascular complications of ribociclib in breast cancer patients.
Fiste O, Mavrothalassitis E, Apostolidou K, Trika C, Liontos M, Koutsoukos K, Kaparelou M, Dimitrakakis C, Gavriatopoulou M, Dimopoulos MA, Zagouri F. Fiste O, et al. Among authors: zagouri f. Crit Rev Oncol Hematol. 2024 Apr;196:104296. doi: 10.1016/j.critrevonc.2024.104296. Epub 2024 Feb 22. Crit Rev Oncol Hematol. 2024. PMID: 38395242 Review.
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Dimitrakopoulos FI, Goussia A, Koliou GA, Dadouli K, Batistatou A, Kourea HP, Bobos M, Arapantoni-Dadioti P, Tzaida O, Koletsa T, Chrisafi S, Sotiropoulou M, Papoudou-Bai A, Nicolaou I, Charchanti A, Mauri D, Aravantinos G, Binas I, Res E, Psyrri A, Pectasides D, Bafaloukos D, Koumarianou A, Bompolaki I, Rigakos G, Karanikiotis C, Koutras A, Zagouri F, Gogas H, Fountzilas G. Dimitrakopoulos FI, et al. Among authors: zagouri f. Breast. 2024 Feb;73:103668. doi: 10.1016/j.breast.2023.103668. Epub 2023 Dec 25. Breast. 2024. PMID: 38176305 Free PMC article.
The Role of Exercise in Cancer-Related Sarcopenia and Sarcopenic Obesity.
Papadopetraki A, Giannopoulos A, Maridaki M, Zagouri F, Droufakou S, Koutsilieris M, Philippou A. Papadopetraki A, et al. Among authors: zagouri f. Cancers (Basel). 2023 Dec 15;15(24):5856. doi: 10.3390/cancers15245856. Cancers (Basel). 2023. PMID: 38136400 Free PMC article. Review.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
Defining Oligometastatic Bladder Cancer: A Systematic Review.
Bamias A, Stenzl A, Zagouri F, Andrikopoulou A, Hoskin P. Bamias A, et al. Among authors: zagouri f. Eur Urol Open Sci. 2023 Aug 22;55:28-37. doi: 10.1016/j.euros.2023.08.003. eCollection 2023 Sep. Eur Urol Open Sci. 2023. PMID: 37662704 Free PMC article. Review.
Prolonged impact of anti-cancer therapy on endothelial function and arterial stiffness in breast cancer patients.
Anastasiou M, Oikonomou E, Theofilis P, Papamikroulis GA, Gazouli M, Kalogeras K, Lygkoni S, Pesiridis T, Goliopoulou A, Papatheodoridi A, Psyrri A, Zagouri F, Siasos G, Tousoulis D. Anastasiou M, et al. Among authors: zagouri f. Vascul Pharmacol. 2023 Oct;152:107195. doi: 10.1016/j.vph.2023.107195. Epub 2023 Jul 15. Vascul Pharmacol. 2023. PMID: 37455009
Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer.
Andrikopoulou A, Theofanakis C, Markellos C, Kaparelou M, Koutsoukos K, Apostolidou K, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Zagouri F, Liontos M. Andrikopoulou A, et al. Among authors: zagouri f. Cancers (Basel). 2023 Jul 6;15(13):3519. doi: 10.3390/cancers15133519. Cancers (Basel). 2023. PMID: 37444629 Free PMC article.
276 results